2020 Annual Meeting On-Demand: Full Access (Sat-Mon Sessions)


By far the best value to watch all the educational sessions from the 2020 AABB Annual Meeting and earn continuing education credit. This package includes 79 sessions which are eligible for up to:

  • 81 General Participation credits
  • 72 Continuing Medical Education credits (CME) for physicians
  • 81 California Lab Personnel, Florida Lab Personnel or California Nurse contact hours.

If purchasing each session individually the cost is $1,570/$1,960 (member/nonmember). Access is available through December 31, 2022 so purchase this package today.

Residents/Fellows/Students – AABB is pleased to offer a reduced rate of $149/$199 (that’s more than $350 off the list price). Simply email a signed a letter from your institution/Program Director and/or current student transcript verifying your status to eLearning@aabb.org.

Virtual meeting attendees - AABB will extend the discounted price of $249/$299 (member/nonmember) for purchase of this package. Contact eLearning@aabb.org to receive a promocode to use to register. 

Purchase of this package includes the on-demand recording and a downloadable MP3 audio file for each session. Presentation handouts are not available/included.

Members: $499.00
Standard: $599.00

Products

AM20-42: Rh Disease: Still a Global Problem

Preview Available

AM20-42: Rh Disease: Still a Global Problem

Oct 5, 2020 3:45pm ‐ Oct 5, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Despite regulatory approval in 1968 for the human use of Rh(D) immune globulin to prevent Rh disease of the fetus and newborn, Rh disease still occurs in many parts of the world. In fact, Rh(D) immune globulin is ~99% effective at preventing Rh disease when women receive the drug both antepartum and postpartum. As a result, Rh disease has virtually disappeared from Western Europe, Canada, the United States, and Australia. However, due to a lack of education, awareness, and availability of the drug, Rh disease remains prevalent in other parts of the world, leading to hundreds of thousands of families affected by repeated miscarriages, stillbirths, and neonates with hyperbilirubinemia-related adverse outcomes, including kernicterus spectrum disorder. Indeed, it is estimated that ~50% of the pregnant women around the world who need Rh(D) immune globulin do not receive it, which amounts to ~2.5 million women each year.

This educational session will provide up-to-date information regarding the continuing global burden of disease for this disorder, explore the reasons why this problem persists, and offer potential solutions for remediation. It will also provide attendees with the most current consensus approaches for preventing Rh disease in various clinical settings. Finally, several new therapeutic approaches have been recently proposed to prevent and/or treat Rh disease, in particular, and other variants of hemolytic disease of the fetus and newborn, in general; these will be described along with a discussion of their underlying therapeutic mechanisms.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-43: Strategies for Mitigating Human Error in Transfusion Medicine

Preview Available

AM20-43: Strategies for Mitigating Human Error in Transfusion Medicine

Oct 5, 2020 3:45pm ‐ Oct 5, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Medical error continues to be a problem bedeviling the practice of transfusion medicine (TM). Whether the major contributor to error is 'systems error' or 'human error' is not fully understood. However, eliminating or mitigating different kinds of errors will require different approaches and specific strategies. This session will focus on strategies for mitigating human error in TM. Speakers in this session will present three different strategies. One speaker will discuss the topic cognitive bias as source of error and present a range of bias mitigation approaches that have been implemented with some success to reduce error in other medical specialties. A second speaker will present a recent innovative approach of User-Centered Design (UCD) that was successfully implemented at a major academic medical center to reduce errors in blood product orders and order sets. A third speaker will present a range of strategies implemented by the SHOT (Serious Hazards of Transfusion) group in the United Kingdom over a period of years to mitigate human error. The session will provide attendees with an enhanced understanding of the nature of human error, and with a range of strategies to mitigate this form of error. The audience will be invited to participate by describing their own experiences with human error in TM, and to suggest strategies for mitigating it.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-44: Delivering Next Generation Cell and Gene Therapies: Toward FDA Approval for Early Stage Clinical Trials

Preview Available

AM20-44: Delivering Next Generation Cell and Gene Therapies: Toward FDA Approval for Early Stage Clinical Trials

Oct 5, 2020 3:45pm ‐ Oct 5, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

This session will provide an overview of cell and gene therapy product development from proof-of-concept to an FDA (Food and Drug Administration)- approved clinical therapy. Speakers will address technology transfer from the academic or industry research lab to the clinical manufacturing facility. Key strategic contracts and agreements will be described. Steps required for translation to a clinical grade product including scale-up or scale-out, closed manufacturing processes, transition to clinical grade reagents and supplies and assay development will be discussed. Finally, refining the manufacturing process for IND (Investigational New Drug) submission including validation, lot release testing and stability studies will be demonstrated. Examples will include contemporary cell and gene therapy products currently progressing through clinical trials. The speakers are Principal Investigators from three of the five cell processing facilities contracted by The Production Assistance for Cellular Therapies (PACT) Program - a National Heart, Lung, and Blood Institute (NHLBI) funded resource initiative created to provide support for cell therapy-based IND-enabling translational research.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-45: Automated Hemovigilance: Fast Healthcare Interoperability Resources (FHIR) and Big Data Analysis

Preview Available

AM20-45: Automated Hemovigilance: Fast Healthcare Interoperability Resources (FHIR) and Big Data Analysis

Oct 5, 2020 6:00pm ‐ Oct 5, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Effective blood product safety monitoring faces many obstacles, including difficulty detecting unreported adverse reactions to blood transfusion and difficulty recognizing actionable patterns in the sheer volume of potentially relevant clinical data due to lack of standardized reporting. For example, signs and symptoms of transfusion reactions may be buried in the free text of nurses’ notes and vital signs flowsheets, making automated review problematic. Access to administrative data and missing patient information are additional challenges.

The U.S. Center for Biologics Evaluation and Research (CBER) is addressing these obstacles through its Biologics Effectiveness and Safety (BEST) system. Launched in October 2017, this program seeks to expand and enhance access to new and better data sources, methods, tools, expertise, and infrastructure to conduct surveillance and epidemiologic studies. Standardized data models such as the HL7 Fast Healthcare Interoperability Resources (FHIR) and secure data exchange protocols such as "SMART on FHIR" can facilitate the development of innovative approaches to utilizing electronic health records (EHR) effectively in order to establish semi-automated adverse event identification, validation, and reporting. To solve the challenge of embedded EHR text, natural language processing and other machine learning methods are potentially powerful approaches. The future in this area is very promising, but success will require close collaboration between numerous disciplines, including clinical stakeholders, “big data” scientists, and informatics experts.

In this session, we will define the basic concepts related to “big data” analysis, including data management, interoperability, exchange of protected health information, and machine learning. We will then discuss how these concepts are currently being employed in the application of blood safety through the BEST system. Finally, we will address successes and challenges of this approach, as well as the potential benefits of public-private partnerships in blood safety and beyond.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-46: Preparing Your Transfusion Service and Cellular Therapy Laboratory for Clinical Trials

Preview Available

AM20-46: Preparing Your Transfusion Service and Cellular Therapy Laboratory for Clinical Trials

Oct 5, 2020 6:00pm ‐ Oct 5, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

Transfusion medicine, including blood bank, apheresis and the cellular therapy laboratory, is an integral part of a multitude and ever-growing number of clinical trials and investigations for medical innovation. Given the rapid evolution of therapies and interventions for which transfusion medicine services are required, it has become imperative that transfusion medicine professionals be well versed in the clinical trials process.

During pre-clinical and clinical development of new therapies, safety and clinical efficacy are studied. Understanding the general process of clinical trials as they progress through preparation and development, execution, and closing will help empower transfusion medicine professionals to actively participate in the process. Transfusion medicine services may be inundated with clinical trials for new therapies sponsored by industry so familiarity with different approaches to handling these trials from a transfusion medicine perspective is critical. In addition, innovation in transfusion medicine and development of clinical trials that are investigator- initiated is an integral part for the advancement of any field. Knowing how to start a clinical trial is important for academic investigators to advance their careers.

This session is designed to highlight important aspects of clinical trials development and participation that are relevant to the transfusion medicine community, with examples from blood bank, apheresis and cellular therapy laboratories.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-47: Oral Abstract Session -- Rh: Molecular and Clinical Applications

Preview Available

AM20-47: Oral Abstract Session -- Rh: Molecular and Clinical Applications

Oct 5, 2020 6:00pm ‐ Oct 5, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Rh: Molecular and Clinical Applications

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-48: Incident and Error Reporting: Leveraging the Opportunities for Safer Transfusions

Preview Available

AM20-48: Incident and Error Reporting: Leveraging the Opportunities for Safer Transfusions

Oct 5, 2020 7:15pm ‐ Oct 5, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Many improvements in blood safety have rightfully focused on reducing the risks of blood transfusion that are donor-associated, namely reducing the risk of transfusion transmitted infection and the risk of transfusion related acute lung injury. To that end Hemovigilance systems collect transfusion reaction data that serves to validate national or regional changes in blood collection, manufacturing, and testing to make blood products safer than ever. An under-recognized area of the Hemovigilance systems is the collection of errors and incidents associated with identification, selection, storage, and administration of blood products at the hospital level. While reported events may not culminate in harms reaching case-specific patients, they reflect conditions that are conducive to injuries as significant as mis-transfusion or circulatory overload. Hospitals may be limiting in their power to mitigate reactions related to external, upstream factors, but they have opportunities to identify and rectify process errors culminating in harm.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-49: Updates from the 2019 National Blood Collection and Utilization Survey (NBCUS) and Beyond

Preview Available

AM20-49: Updates from the 2019 National Blood Collection and Utilization Survey (NBCUS) and Beyond

Oct 5, 2020 7:15pm ‐ Oct 5, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

The biennial National Blood Collection and Utilization Survey (NBCUS) provides the most comprehensive estimation of blood collection and utilization in the United States. The NBCUS collects data on the number of units collected, processed, outdated, discarded, and transfused. The survey includes all blood collection facilities and a sample of acute care hospitals operating in the U.S. Since 2013, the NBCUS is being conducted by the Office of the Assistant Secretary of Health and the Centers for Disease Control and Prevention (CDC). The latest NBCUS results available in the public domain is from the survey year 2017. During the session, preliminary findings from the 2019 NBCUS, including national estimates for RBC, whole blood, platelet, plasma, and cryoprecipitate collection, transfusion, and outdates as well as median cost paid by hospitals, will be presented. Furthermore, blood component demand data for the first two quarters of 2020 will be presented in aggregate from the blood centers’ side. The presentations will include discussion about the implications of the current trends on maintaining blood safety and availability. The session will also briefly explore the interpretation of the findings to the current business performance trends in the blood collection industry.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-61: 2020 BB/SBB Exam Review

Preview Available

AM20-61: 2020 BB/SBB Exam Review

Oct 5, 2020 9:00pm ‐ Oct 5, 2020 9:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

The program attendee will attain a concise and targeted review of blood banking and transfusion medicine. All the information needed to pass the ASCP SBB or BB exams are briefly reviewed in a three-hour program. This program attempts to provide the attendee with the structure, information and encouragement to tackle these exams. This program will provide a plan for those preparing for the ASCP BB or SBB exam. The specific content areas of the exams highlighting where to find information required for successful completion of these exams. Whether a refresher, a review or new learning, the program attendee will benefit from the comprehensive summary of blood banking and transfusion medicine provided by this course.

Speaker(s):
Standard: $35.00
Members: $30.00

AM20-62: Advances in Understanding of RBC Alloimmunization - Mechanisms and Interventions

Preview Available

AM20-62: Advances in Understanding of RBC Alloimmunization - Mechanisms and Interventions

Oct 5, 2020 9:00pm ‐ Oct 5, 2020 9:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Over the last decade, significant innovation has taken place with regards to our mechanistic understanding of immunization to alloantigens on transfused red blood cells (RBCs). Mechanistic innovation has been driven largely by advanced animal modeling that has led to follow up human studies. Conversely, innovative human studies have also led to new questions that have resulted in advances in animal models. In this bidirectional use of animal and human studies, substantial progress has been made in both mechanistic understanding, human epidemiology, and the generation of potential therapeutic interventions. Moreover, the combination of animal and human studies have allowed a careful determination of what basic findings do, or do not, translate into human biology – providing a careful strategic metric for relevant and translatable scientific inquiry. This session serves to inform the audience of recent advances and also communicate the current existing landscape of tools and systems available for ongoing discovery.

Speaker(s):
Standard: $25.00
Members: $20.00
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content